Failure of Dopexamine to Maintain Haemodynamic Improvement in Patients with Chronic Heart Failure

Overview

Journal Br Heart J

Specialty Cardiology & Vascular Diseases

Date 1988 Jul 1

PMID 2900644

Citations 4

Authors

J J Murphy

J R Hampton

Affiliations

Soon will be listed here.

Abstract

Ten patients with chronic heart failure were given a continuous infusion of dopexamine after an initial stage of dose titration. On the dose selected the cardiac index initially rose by 56%, as a result of an increase in both heart rate and stroke volume index. Systemic vascular resistance fell by 34% and the mean arterial pressure did not change. Within 18 hours of the start of the continuous infusion, however, all the variables except heart rate had returned to preinfusion values. Nine of the 10 patients were withdrawn from the 48 hour study, six because of haemodynamic deterioration and two because of side effects. If the premature loss of therapeutic effect reflects an intrinsic property of this agent, dopexamine may be of limited clinical value.

Citing Articles

Effects of chronic intravenous infusions of dopexamine and isoprenaline to rats on D1-, beta 1- and beta 2-receptor-mediated responses.

Martin S, Broadley K Br J Pharmacol. 1994; 112(2):595-603.

PMID: 7915614 PMC: 1910351. DOI: 10.1111/j.1476-5381.1994.tb13116.x.

Dopexamine in congestive heart failure: how do the pharmacological activities translate into the clinical situation?.

Meinertz T, Drexler H, Just H Basic Res Cardiol. 1989; 84 Suppl 1:177-86.

PMID: 2573340 DOI: 10.1007/BF02650357.

The effects of dopexamine, a new dopamine analogue, on platelet function in stress.

Hendra T, Smith C, Yudkin J Br J Clin Pharmacol. 1990; 30(1):87-95.

PMID: 2390435 PMC: 1368279. DOI: 10.1111/j.1365-2125.1990.tb03747.x.

Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency.

Fitton A, Benfield P Drugs. 1990; 39(2):308-30.

PMID: 1970288 DOI: 10.2165/00003495-199039020-00009.

References

Goldberg L . Dopamine--clinical uses of an endogenous catecholamine. N Engl J Med. 1974; 291(14):707-10. DOI: 10.1056/NEJM197410032911405. View

Tan L . Cardiac pumping capability and prognosis in heart failure. Lancet. 1986; 2(8520):1360-3. DOI: 10.1016/s0140-6736(86)92006-4. View

Leier C, Webel J, Bush C . The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation. 1977; 56(3):468-72. DOI: 10.1161/01.cir.56.3.468. View

Johnson G, Wolfe B, Harden T, Molinoff P, PERKINS J . Role of beta-adrenergic receptors in catecholamine-induced desensitization of adenylate cyclase in human astrocytoma cells. J Biol Chem. 1978; 253(5):1472-80. View

Unverferth D, Blanford M, Kates R, Leier C . Tolerance to dobutamine after a 72 hour continuous infusion. Am J Med. 1980; 69(2):262-6. DOI: 10.1016/0002-9343(80)90387-3. View

Colucci W, Alexander R, Williams G, Rude R, HOLMAN B, Konstam M . Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med. 1981; 305(4):185-90. DOI: 10.1056/NEJM198107233050402. View

Miller R, Palomo A, Brandon T, Hartley C, Quinones M . Combined vasodilator and inotropic therapy of heart failure: experimental and clinical concepts. Am Heart J. 1981; 102(3 Pt 2):500-8. DOI: 10.1016/0002-8703(81)90738-9. View

BROWN R, DIXON J, Farmer J, Hall J, Humphries R, Ince F . Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors. Br J Pharmacol. 1985; 85(3):599-608. PMC: 1916510. DOI: 10.1111/j.1476-5381.1985.tb10554.x. View

BROWN R, Farmer J, Hall J, Humphries R, OConnor S, Smith G . The effects of dopexamine on the cardiovascular system of the dog. Br J Pharmacol. 1985; 85(3):609-19. PMC: 1916515. DOI: 10.1111/j.1476-5381.1985.tb10555.x. View

10.

Dawson J, Thompson D, Signy M, Juul S, Turnbull P, Jenkins B . Acute haemodynamic and metabolic effects of dopexamine, a new dopaminergic receptor agonist, in patients with chronic heart failure. Br Heart J. 1985; 54(3):313-20. PMC: 481901. DOI: 10.1136/hrt.54.3.313. View

11.

Vatner D, Vatner S, Fujii A, Homcy C . Loss of high affinity cardiac beta adrenergic receptors in dogs with heart failure. J Clin Invest. 1985; 76(6):2259-64. PMC: 424349. DOI: 10.1172/JCI112235. View

12.

Ruffolo Jr R, Kopia G . Importance of receptor regulation in the pathophysiology and therapy of congestive heart failure. Am J Med. 1986; 80(2B):67-72. DOI: 10.1016/0002-9343(86)90148-8. View

13.

Jaski B, Wijns W, Foulds R, Serruys P . The haemodynamic and myocardial effects of dopexamine: a new beta 2-adrenoceptor and dopaminergic agonist. Br J Clin Pharmacol. 1986; 21(4):393-400. PMC: 1400939. DOI: 10.1111/j.1365-2125.1986.tb05213.x. View

14.

McGrath B, Arnolda L . Enalapril reduces the catecholamine response to exercise in patients with heart failure. Eur J Clin Pharmacol. 1986; 30(4):485-7. DOI: 10.1007/BF00607965. View

15.

Svensson G, Sjogren A, Erhardt L . Short-term haemodynamic effects of dopexamine in patients with chronic congestive heart failure. Eur Heart J. 1986; 7(8):697-703. DOI: 10.1093/oxfordjournals.eurheartj.a062125. View

16.

Heitz A, Schwartz J, VELLY J . Beta-adrenoceptors of the human myocardium: determination of beta 1 and beta 2 subtypes by radioligand binding. Br J Pharmacol. 1983; 80(4):711-7. PMC: 2045057. DOI: 10.1111/j.1476-5381.1983.tb10062.x. View

17.

Loeb H, Bredakis J, Gunner R . Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure. Circulation. 1977; 55(2):375-8. DOI: 10.1161/01.cir.55.2.375. View